Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thiopefilgrastim to prevent neutropenia during neoadjuvant chemoradiotherapy for esophageal cancer
ChiCTR2100046406Phase 4Recruiting
- Sponsor
- Quanzhou First Hospital
- Start
- Mar 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mecapegfilgrastim in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Quanzhou First Hospital. Primary endpoint: Incidence of grade ≥3 neutropenia during concurrent chemoradiotherapy. Started Mar 2021; status: recruiting.
02
Drugs
mecapegfilgrastim
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2100046406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046406.